• Home
  • About medac
  • Information for patients
  • Healthcare professionals
  • Products
  • Career opportunities
  • Media
  • Dealing with the COVID-19 pandemic

    Guideline for cancer patients

    New and unique
    SARS-CoV-2 surrogate neutralisation test

    For the first time, with the cPass test, there is now a method available to anyone to test the blocking effect of neutralising COVID-19 antibodies.

    Find out more

    To our job offers

    No matter whether you are looking for an internship, a job as a university graduate or you want to take the next step in your career as an applicant with work experience: You can find the whole spectrum on the following pages.

    Find our more


    Our expertise as a pharmaceutical company

    medac is a future-oriented company and has been growing dynamically since fifty years. More than 2000 medac employees work on the first-time development and further refinement of pharmaceuticals and medical products for the diagnosis and treatment of oncological, urological and auto-immune diseases. Especially when it is a question of niche products we are one of the leading pharmaceutical companies. We represent solid values and basically think in human terms. This results in long-lasting business partnership relations with clinics, doctors and laboratories, as well as providing a healthy working atmosphere for all our employees




    Press Release

    medac GmbH: New Management structure

    A reliable diagnosis with the new cPass test by medac GmbH

    Is it possible that I’m already immune to COVID-19?

    In the time of lockdowns and vaccination chaos, a new diagnostic procedure finally provides...

    medac statement on Coronavirus (SARS-CoV-2)

    At this moment in time, and after consultation of the competent authorities, we do not foresee any interruptions in production and therefore no supply...

    Trecondi® - the new original from medac

    After 20 years of intensive research and development activity in the field of haematology and oncology, medac received EU-wide marketing authorisation...

    Delivery failure urokinase

    Urokinase medac is not available at the moment. At present, work is underway on a new production of the drug in order to provide patients with...

    medac at the EBMT 2019

    Innovative conditioning therapy for MDS and AML

    Warning of the off-label use of BCG-medac for the prevention (vaccination) or treatment of COVID-19

    The experimental use of BCG-medac as a vaccine against COVID-19 is associated with a high risk of serious adverse reactions and should therefore be strictly avoided. The Federal Institute for Vaccines and Biomedical Medicines (Paul-Ehrlich Institut (PEI)) has published a respective safety information:


    No news available.
    Nach oben